The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...

U.S. stocks are down in morning trading Friday, pulling the market back from all-time highs, as the Trump administration ...

Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

This was the stock's second consecutive day of gains.

We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

Gilead Sciences' profit was reduced by unusual items worth US$3.3b in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items.

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.